Whitehawk Therapeutics, Inc. WHWK
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK) is an oncology drug developer. Its lead program, HWK-007, is in Phase 1 for Solid tumors incl. NSCLC and ovarian cancer (PTK7 ADC). Its next catalyst on record is HWK-206: FDA clearance of IND (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: HWK-206 — FDA clearance of IND (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| HWK-007 (PTK7 ADC) | NSCLC, ovarian | biologic-other | Phase 1 |
| HWK-016 (MUC16 ADC) | Ovarian, endometrial | biologic-other | Phase 1 |
| HWK-206 (SEZ6 ADC) | SCLC, NETs | biologic-other | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.